Parenteral Ascorbate As a Cancer Therapeutic: A Reassessment Based on Pharmacokinetics
Publication: Antioxidants & Redox Signaling
Volume 19, Issue Number 17
Abstract
Significance: Ewan Cameron reported that ascorbate, given orally and intravenously at doses of up to 10 g/day, was effective in the treatment of cancer. Double-blind placebo-controlled clinical trials showed no survival advantage when the same doses of ascorbate were given orally, leading the medical and scientific communities to dismiss the use of ascorbate as a potential cancer treatment. However, the route of administration results in major differences in ascorbate bioavailability. Tissue and plasma concentrations are tightly controlled in response to oral administration, but this can be bypassed by intravenous administration. These data provide a plausible scientific rationale for the absence of a response to orally administered ascorbate in the Mayo clinic trials and indicate the need to reassess ascorbate as a cancer therapeutic. Recent Advances: High dose ascorbate is selectively cytotoxic to cancer cell lines through the generation of extracellular hydrogen peroxide (H2O2). Murine xenograft models confirm a growth inhibitory effect of pharmacological concentrations. The safety of intravenous ascorbate has been verified in encouraging pilot clinical studies. Critical Issues: Neither the selective toxicity of pharmacologic ascorbate against cancer cells nor the mechanism of H2O2-mediated cytotoxicity is fully understood. Despite promising preclinical data, the question of clinical efficacy remains. Future Directions: A full delineation of mechanism is of interest because it may indicate susceptible cancer types. Effects of pharmacologic ascorbate used in combination with standard treatments need to be defined. Most importantly, the clinical efficacy of ascorbate needs to be reassessed using proper dosing, route of administration, and controls. Antioxid. Redox Signal. 19, 2141–2156.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Abdel-Latif MM, Raouf AA, Sabra K, Kelleher D, and Reynolds JV. Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother 17: 539–549, 2005.
2.
Andersson DA, Gentry C, Alenmyr L, Killander D, Lewis SE, Andersson A, Bucher B, Galzi JL, Sterner O, Bevan S, Hogestatt ED, and Zygmunt PM. TRPA1 mediates spinal antinociception induced by acetaminophen and the cannabinoid Delta(9)-tetrahydrocannabiorcol. Nat Commun 2: 551, 2011.
3.
Belin S, Kaya F, Duisit G, Giacometti S, Ciccolini J, and Fontes M. Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One 4: e4409, 2009.
4.
Bown SR. Scurvy: How a Surgeon, a Mariner, and a Gentleman Solved the Greatest Medical Mystery of the Age of Sail. New York: Thomas Dunne Books, 2004, p 254.
5.
Cameron E and Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9: 285–315, 1974.
6.
Cameron E, Campbell A, and Jack T. The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact 11: 387–393, 1975.
7.
Cameron E and Pauling L. Ascorbic acid and the glycosaminoglycans. An orthomolecular approach to cancer and other diseases. Oncology 27: 181–192, 1973.
8.
Cameron E and Pauling L. The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem Biol Interact 9: 273–283, 1974.
9.
Cameron E and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73: 3685–3689, 1976.
10.
Cameron E and Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75: 4538–4542, 1978.
11.
Cameron E, Pauling L, and Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res 39: 663–681, 1979.
12.
Cameron E and Rotman D. Ascorbic acid, cell proliferation, and cancer. Lancet 1: 542, 1972.
13.
Carosio R, Zuccari G, Orienti I, Mangraviti S, and Montaldo PG. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer 6: 55, 2007.
14.
Chen MF, Yang CM, Su CM, Liao JW, and Hu ML. Inhibitory effect of vitamin C in combination with vitamin K3 on tumor growth and metastasis of Lewis lung carcinoma xenografted in C57BL/6 mice. Nutr Cancer 63: 1036–1043, 2011.
15.
Chen P, Stone J, Sullivan G, Drisko JA, and Chen Q. Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med 51: 681–687, 2011.
16.
Chen P, Yu J, Chalmers B, Drisko J, Yang J, Li B, and Chen Q. Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs 23: 437–444, 2012.
17.
Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, and Levine M. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102: 13604–13609, 2005.
18.
Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, Choyke PL, Pooput C, Kirk KL, Buettner GR, and Levine M. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A 104: 8749–8754, 2007.
19.
Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, and Levine M. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105: 11105–11109, 2008.
20.
Corpe CP, Tu H, Eck P, Wang J, Faulhaber-Walter R, Schnermann J, Margolis S, Padayatty S, Sun H, Wang Y, Nussbaum RL, Espey MG, and Levine M. Vitamin C transporter Slc23a1 links renal reabsorption, vitamin C tissue accumulation, and perinatal survival in mice. J Clin Invest 120: 1069–1083, 2010.
21.
Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, and Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301: 687–690, 1979.
22.
Deubzer B, Mayer F, Kuci Z, Niewisch M, Merkel G, Handgretinger R, and Bruchelt G. H(2)O(2)-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol Biochem 25: 767–774, 2010.
23.
Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, and Cullen JJ. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16: 509–520, 2010.
24.
Espey MG, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, and Chen Q. Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50: 1610–1619, 2011.
25.
Espey MG, Chen Q, and Levine M. Comment re: vitamin C antagonizes the cytotoxic effects of chemotherapy. Cancer Res 69: 8830; author reply 8830–8831, 2009.
26.
Fleming RE and Ponka P. Iron overload in human disease. N Engl J Med 366: 348–359, 2012.
27.
Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, and Aigner A. Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 67: 1157–1166, 2011.
28.
Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, and Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 98: 805–813, 2001.
29.
Graumlich JF, Ludden TM, Conry-Cantilena C, Cantilena LR Jr., Wang Y, and Levine M. Pharmacokinetic model of ascorbic acid in healthy male volunteers during depletion and repletion. Pharm Res 14: 1133–1139, 1997.
30.
Hahm E, Jin DH, Kang JS, Kim YI, Hong SW, Lee SK, Kim HN, Jung da J, Kim JE, Shin DH, Hwang YI, Kim YS, Hur DY, Yang Y, Cho D, Lee MS, and Lee WJ. The molecular mechanisms of vitamin C on cell cycle regulation in B16F10 murine melanoma. J Cell Biochem 102: 1002–1010, 2007.
31.
Han SS, Kim K, Hahm ER, Lee SJ, Surh YJ, Park HK, Kim WS, Jung CW, Lee MH, Park K, Yang JH, Yoon SS, Riordan NH, Riordan HD, Kimler BF, Park CH, Lee JH, and Park S. L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem 93: 257–270, 2004.
32.
Heaney ML, Gardner JR, Karasavvas N, Golde DW, Scheinberg DA, Smith EA, and O'Connor OA. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68: 8031–8038, 2008.
33.
Herst PM, Broadley KW, Harper JL, and McConnell MJ. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med 52: 1486–1493, 2012.
34.
Hoffer LJ. Proof versus plausibility: rules of engagement for the struggle to evaluate alternative cancer therapies. CMAJ 164: 351–353, 2001.
35.
Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, and Miller WH Jr., Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19: 1969–1974, 2008.
36.
Hong SW, Jin DH, Hahm ES, Yim SH, Lim JS, Kim KI, Yang Y, Lee SS, Kang JS, Lee WJ, Lee WK, and Lee MS. Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep 18: 811–815, 2007.
37.
Hong SW, Lee SH, Moon JH, Hwang JJ, Kim DE, Ko E, Kim HS, Cho IJ, Kang JS, Kim DJ, Kim JE, Shin JS, Jung DJ, Jeong YJ, Cho BJ, Kim TW, Lee JS, Kang JS, Hwang YI, Noh DY, Jin DH, and Lee WJ. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene [Epub ahead of print];.
38.
Kang JS, Cho D, Kim YI, Hahm E, Yang Y, Kim D, Hur D, Park H, Bang S, Hwang YI, and Lee WJ. L-ascorbic acid (vitamin C) induces the apoptosis of B16 murine melanoma cells via a caspase-8-independent pathway. Cancer Immunol Immunother 52: 693–698, 2003.
39.
Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 149: 43–50, 2000.
40.
Kim J, Lee SD, Chang B, Jin DH, Jung SI, Park MY, Han Y, Yang Y, Il Kim K, Lim JS, Kang YS, and Lee MS. Enhanced antitumor activity of vitamin C via p53 in cancer cells. Free Radic Biol Med 53: 1607–1615, 2012.
41.
Klingelhoeffer C, Kammerer U, Koospal M, Muhling B, Schneider M, Kapp M, Kubler A, Germer CT, and Otto C. Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress. BMC Complement Altern Med 12: 61, 2012.
42.
Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, and Bruckner HW. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 103: 183–189, 1996.
43.
Lee SK, Kang JS, Jung da J, Hur DY, Kim JE, Hahm E, Bae S, Kim HW, Kim D, Cho BJ, Cho D, Shin DH, Hwang YI, and Lee WJ. Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor II (IGF-II) production. J Cell Physiol 216: 180–188, 2008.
44.
Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, and Cantilena LR. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 93: 3704–3709, 1996.
45.
Levine M, Wang Y, Padayatty SJ, and Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A 98: 9842–9846, 2001.
46.
Li H, Tu H, Wang Y, and Levine M. Vitamin C in mouse and human red blood cells: an HPLC assay. Anal Biochem 426: 109–117, 2012.
47.
Li L, Ishdorj G, and Gibson SB. Reactive oxygen species regulation of autophagy in cancer: Implications for cancer treatment. Free Radic Biol Med 53: 1399–1410, 2012.
48.
Lim D, Morgan RJ Jr., Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, and Doroshow JH. Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Invest New Drugs 23: 235–239, 2005.
49.
Lin SY, Lai WW, Chou CC, Kuo HM, Li TM, Chung JG, and Yang JH. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res 16: 509–519, 2006.
50.
Lin ZY and Chuang WL. Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 64: 348–351, 2010.
51.
Martinotti S, Ranzato E, and Burlando B. In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro 25: 1568–1574, 2011.
52.
Mc CW. Cancer: a collagen disease, secondary to a nutritional deficiency. Arch Pediatr 76: 166–171, 1959.
53.
Mikirova NA, Ichim TE, and Riordan NH. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med 6: 50, 2008.
54.
Mitchell JB, Samuni A, Krishna MC, DeGraff WG, Ahn MS, Samuni U, and Russo A. Biologically active metal-independent superoxide dismutase mimics. Biochemistry 29: 2802–2807, 1990.
55.
Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, and Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312: 137–141, 1985.
56.
Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, and Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7: e29794, 2012.
57.
Padayatty SJ and Levine M. New insights into the physiology and pharmacology of vitamin C. Cmaj 164: 353–355, 2001.
58.
Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, and Levine M. Intravenously administered vitamin C as cancer therapy: three cases. Cmaj 174: 937–942, 2006.
59.
Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, and Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5: e11414, 2010.
60.
Padayatty SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA, and Levine M. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140: 533–537, 2004.
61.
Park S, Ahn ES, Lee S, Jung M, Park JH, Yi SY, and Yeom CH. Proteomic analysis reveals upregulation of RKIP in S-180 implanted BALB/C mouse after treatment with ascorbic acid. J Cell Biochem 106: 1136–1145, 2009.
62.
Pathi SS, Lei P, Sreevalsan S, Chadalapaka G, Jutooru I, and Safe S. Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer 63: 1133–1142, 2011.
63.
Patterson JW. Course of diabetes and development of cataracts after injecting dehydroascorbic acid and related substances. Am J Physiol 165: 61–65, 1951.
64.
Perrone G, Hideshima T, Ikeda H, Okawa Y, Calabrese E, Gorgun G, Santo L, Cirstea D, Raje N, Chauhan D, Baccarani M, Cavo M, and Anderson KC. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23: 1679–1686, 2009.
65.
Pollard HB, Levine MA, Eidelman O, and Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24: 249–255, 2010.
66.
Ranzato E, Biffo S, and Burlando B. Selective ascorbate toxicity in malignant mesothelioma: a redox Trojan mechanism. Am J Respir Cell Mol Biol 44: 108–117, 2011.
67.
Riordan HD, Casciari JJ, Gonzalez MJ, Riordan NH, Miranda-Massari JR, Taylor P, and Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J 24: 269–276, 2005.
68.
Riordan HD, Riordan NH, Jackson JA, Casciari JJ, Hunninghake R, Gonzalez MJ, Mora EM, Miranda-Massari JR, Rosario N, and Rivera A. Intravenous vitamin C as a chemotherapy agent: a report on clinical cases. P R Health Sci J 23: 115–118, 2004.
69.
Riordan NH, Riordan HD, Meng X, Li Y, and Jackson JA. Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Med Hypotheses 44: 207–213, 1995.
70.
Rumsey SC, Kwon O, Xu GW, Burant CF, Simpson I, and Levine M. Glucose transporter isoforms GLUT1 and GLUT3 transport dehydroascorbic acid. J Biol Chem 272: 18982–18989, 1997.
71.
Sharpless NE and Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741–754, 2006.
72.
Shinozaki K, Hosokawa Y, Hazawa M, Kashiwakura I, Okumura K, Kaku T, and Nakayama E. Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line. J Radiat Res 52: 229–237, 2011.
73.
Sotiriou S, Gispert S, Cheng J, Wang Y, Chen A, Hoogstraten-Miller S, Miller GF, Kwon O, Levine M, Guttentag SH, and Nussbaum RL. Ascorbic-acid transporter Slc23a1 is essential for vitamin C transport into the brain and for perinatal survival. Nat Med 8: 514–517, 2002.
74.
Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, and Kubota S. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 394: 249–253, 2010.
75.
Ullah MF, Khan HY, Zubair H, Shamim U, and Hadi SM. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 67: 103–110, 2011.
76.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231: 232–235, 1971.
77.
Verrax J and Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47: 32–40, 2009.
78.
Wang Y, Russo TA, Kwon O, Chanock S, Rumsey SC, and Levine M. Ascorbate recycling in human neutrophils: induction by bacteria. Proc Natl Acad Sci U S A 94: 13816–13819, 1997.
79.
Welsh JL, Wagner BA, Van't Erve TJ, Zehr PS, Berg DJ, Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ 2nd, Drisko J, Levine M, Buettner GR, and Cullen JJ. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71: 765–775.
80.
Wu KK. Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. J Lab Clin Med 128: 242–245, 1996.
81.
Yeom CH, Jung GC, and Song KJ. Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22: 7–11, 2007.
82.
Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY, Lee HR, Hong YS, Yang J, and Lee S. High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7: 70, 2009.
Information & Authors
Information
Published In
Antioxidants & Redox Signaling
Volume 19 • Issue Number 17 • December 10, 2013
Pages: 2141 - 2156
PubMed: 23621620
Copyright
Copyright 2013, Mary Ann Liebert, Inc.
History
Published online: 16 December 2013
Published in print: December 10, 2013
Published ahead of print: 19 June 2013
Published ahead of production: 28 April 2013
Accepted: 28 April 2013
Received: 15 April 2013
Topics
Authors
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.